FDA Approves MOUNJARO — Eli Lilly and Company
The FDA has granted full approval to Mounjaro (tirzepatide), Eli Lilly’s once-weekly injectable twincretin agonist, for the treatment of type 2 diabetes mellitus on May 13. This pivotal regulatory milestone significantly enhances the drug’s commercial prospects by allowing for wider physician prescribing and insurancer coverage, strengthening Eli Lilly’s competitive position against market peers.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed